Skip to content

ABioGram system

From antimicrobial susceptibility testing to therapy support

ABioGram validates antimicrobial susceptibility test results for inclusion in microbiology reports. Validated data help monitor antimicrobial resistance and update antimicrobial therapy protocols.

Contact us Download presentation

How ABioGram works

One validated result – two ways to use it.

ABioGram – one workflow

Input

Susceptibility testing of an organism isolated from a patient

MIC · inhibition-zone diameter · S/I/R

Integrated expert assessment

Checking measurements and S/I/R, analyzing the antibiogram as a complete phenotype alongside available genotypic data.

Validated susceptibility result

For the individual patient

Microbiology report

The clinician uses the report with a validated susceptibility result when choosing pathogen-directed antimicrobial therapy.

For local practice

Etiology and AMR

Estimating the activity of agents and regimens informs empiric therapy approaches.

What the system does

ABioGram puts our domain expertise into software tools for the everyday work of healthcare organizations.

01

Expert validation

Validation of antimicrobial susceptibility results before they are used in clinical care.

  • Validation of MICs and zone diameters, S/I/R categorization, and consistency checks.
  • Analysis of the antibiogram as a complete phenotype; identification of unusual and contradictory results.
  • Comparison of phenotype with genotypic data and resistance markers when available.
  • Generation of a validated susceptibility result and relevant expert messages.
02

Microbiology surveillance

Local etiology and antimicrobial resistance data help healthcare leaders assess patterns across departments, organizations and periods.

  • Pathogen distribution, susceptibility, resistance, phenotypes, and markers.
  • Flexible analysis across any available data fields, including infection site, department, patient group and period.
  • Period comparison, drill-down to source records, and patient test history where implemented.
  • Surveillance at healthcare organization, network, or regional level.
03

Antimicrobial agent and regimen activity

Using local data to develop and update empiric antimicrobial therapy approaches.

  • Estimation of activity probabilities for individual antimicrobial agents.
  • Comparison of supported monotherapy and combination regimens.
  • Assessment of therapeutic options in the context of pathogen etiology and susceptibility in the selected local population.

For clinical pharmacologists and the antimicrobial therapy team

Assessing empiric therapy options

ABioGram estimates the activity of agents and supported therapeutic regimens for a selected local pathogen population. These data help update local antimicrobial therapy protocols.

  1. 01

    Define the analysis group

    Infection site, department, patient group, period.

  2. 02

    Estimate activity

    Relate local etiology to antimicrobial susceptibility in that population.

  3. 03

    Compare options

    Individual agents, monotherapy and supported combinations.

The estimate describes microbiological activity in the selected population; it does not predict an individual patient’s clinical outcome.

Domain and methodological foundation

The domain expertise behind expert validation and interpretation of results.

Which guidelines and criteria are used?

Expert assessment draws on documents for different organism groups and test methods:

  • Russian recommendations Determination of susceptibility of microorganisms to antimicrobial agents, version 2025-01.
  • Russian recommendations Determination of susceptibility of microorganisms to antimicrobial agents, version 2026-01.
  • EUCAST Breakpoint tables for interpretation of MICs and zone diameters for bacteria, versions 14.0–16.1.
  • EUCAST Clinical breakpoints for fungi, version 12.1.
  • EUCAST epidemiological cut-off values (ECOFFs).
  • CLSI M100, Performance Standards for Antimicrobial Susceptibility Testing.
  • CLSI M45, Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria.
  • CLSI M27M44S, Performance Standards for Antifungal Susceptibility Testing of Yeasts, 4th ed. (2026).
  • Other relevant documents and recommendations on susceptibility testing and interpretation of microbiology results.
What does expert result validation include?

ABioGram checks MICs, inhibition-zone diameters and S/I/R categories, then evaluates the antibiogram as a complete phenotype. When genotypic data are available, the system compares them with the phenotype.

Expert assessment helps identify unusual and contradictory results and account for intrinsic resistance, indicator agents and limitations on use. The output is a validated result and relevant expert messages for the microbiology report.

LIS/HIS integration and web interface

These are two ways to provide test data to ABioGram and obtain a validated result. With LIS/HIS integration, the scope of data exchange depends on the deployment model.

API exchange

The system receives microbiology test data from LIS/HIS. After validation, it returns the susceptibility result and expert messages for use in the existing workflow.

Working in the web interface

A specialist enters test data and reviews the validated result directly in ABioGram. This approach does not require API data exchange with LIS/HIS.

AMR surveillance takes place in the ABioGram interface; when integrated, an individual test result is returned to LIS/HIS. In a network-wide deployment, multiple healthcare organizations can connect to the system.

Technical capabilities

Deployment, scaling, support, and operating conditions.

Deployment, scaling, and information security
The system can be deployed on premises within a healthcare organization’s or region’s secure environment, accounting for personal-data requirements. The architecture supports high result volumes, networks of institutions, and regional implementations.
Support and licensing
Support includes implementation assistance, consultation, updates, and workflow configuration. Institutional delivery and a complete set of contracting documents are available. The system is listed in Russia’s Unified Register of Russian Software for Computers and Databases.

Publications and evidence base

Scientific materials support the approaches to microbiology data quality, surveillance methodology, local etiology and AMR analysis, and the use of data in antimicrobial therapy.

The product’s official name is the ABioGram reference and information system.

Additional information about ABioGram

Upon request, we provide information about system capabilities, deployment options, and LIS/HIS integration.

Contact usDownload presentation